Zobrazeno 1 - 10
of 1 570
pro vyhledávání: '"Castration resistance"'
Autor:
İvo Gökmen, Nazan Demir, Pınar Peker, Erkan Özcan, Fahri Akgül, İsmail Bayrakçı, Didem Divriklioğlu, Bülent Erdoğan, Sernaz Topaloğlu, Muhammet Bekir Hacıoğlu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveThe aim of our study was to assess the impact of the combination of HALP score with TTCR score on OS and PFS in PC patients who developed castration resistance.Patients and methodsThe study enrolled 152 patients with metastatic disease who h
Externí odkaz:
https://doaj.org/article/52359d4eed0840de98ac9f4e24b298fe
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 1509-1516 (2024)
Monu Deswal,1 Durgavati Yadav,1 Vinay Kumar,2 Meenakshi Meenu,3 Pranay Tanwar,4 Shivani Srivastava,5 Prabhjot Singh,1 Kumar Sandeep6 1Department of Urology, All India Institute of Medical Sciences, New Delhi, India; 2Heart and Vascular Institute, Pen
Externí odkaz:
https://doaj.org/article/3ceed4fc7c6545a8ae5f92ca31da7185
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear whi
Externí odkaz:
https://doaj.org/article/1e1e2cd4773f45ac9de59e8ef355b170
Autor:
Haiyan E. Liu, Meghah Vuppalapaty, Christian R. Hoerner, Colin P. Bergstrom, Michael Chiu, Clementine Lemaire, James Che, Amanpreet Kaur, Adam Dimmick, Sean Liu, Thomas J. Metzner, Menna Araya, Steve Crouse, Markus Sprenger-Haussels, Martin Schlumpberger, John T. Leppert, Siegfried Hauch, Elodie Sollier, Alice C. Fan
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Therapies for metastatic castration-resistant prostate cancer (mCRPC) include targeting the androgen receptor (AR) with androgen receptor inhibitors (ARIs) and prostate-specific membrane antigen (PSMA). Having the ability to detec
Externí odkaz:
https://doaj.org/article/f147876cb7db462d84fa5bc412a8c4d4
Autor:
Robert D. Marek, Selena Halabi, Mu-En Wang, Jason McBane, Junping Wei, Tao Wang, Xiao Yang, Congxiao Liu, Gangjun Lei, Herbert Kim Lyerly, Ming Chen, Timothy N. Trotter, Zachary C. Hartman
Publikováno v:
Vaccines, Vol 12, Iss 11, p 1273 (2024)
Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to targ
Externí odkaz:
https://doaj.org/article/c963995c0b8d4b7f83e39d65de5281db
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate canc
Externí odkaz:
https://doaj.org/article/672bc2832e2547e2b09f6f732c936831
Autor:
Yan Zhao, Jie Liang, Qian Wang, Jing-Yi Cao, Zhi-Xiang Yin, Han-Yong Feng, Yu-Hao Peng, Nian-Xin Gai, Chang-Song Pei
Publikováno v:
Journal of Men's Health, Vol 19, Iss 7, Pp 39-44 (2023)
Presently, there is limited data on the potential survival benefits of transurethral resection of the prostate (TURP) in patients with metastatic hormone-sensitive prostate cancer (mHSPCa). In this study, we aimed to assess the effects of TURP on the
Externí odkaz:
https://doaj.org/article/d1cc9a6821184d6c93a596219891ef56
Autor:
Hiroji Uemura, Mototsugu Oya, Toshiyuki Kamoto, Mikio Sugimoto, Kenta Shinozaki, Kiyomi Morita, Ryo Koto, Mai Takahashi, Masahiro Nii, Eisei Shin, Norio Nonomura
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5265-5274 (2023)
Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well
Externí odkaz:
https://doaj.org/article/249a8ddb0fe749f4a091ed958c53320d
Publikováno v:
Asian Journal of Andrology, Vol 25, Iss 2, Pp 192-197 (2023)
Reprogramming of metabolism is a hallmark of tumors, which has been explored for therapeutic purposes. Prostate cancer (PCa), particularly advanced and therapy-resistant PCa, displays unique metabolic properties. Targeting metabolic vulnerabilities i
Externí odkaz:
https://doaj.org/article/816d74f6dff94c678c766b782961193d
Autor:
Ingrid Jenny Guldvik, Peder Rustøen Braadland, Shivanthe Sivanesan, Håkon Ramberg, Gitte Kristensen, Pierre Tennstedt, Andreas Røder, Thorsten Schlomm, Viktor Berge, Lars Magne Eri, Wolfgang Lilleby, Ian G. Mills, Kristin Austlid Taskén
Publikováno v:
European Urology Open Science, Vol 45, Iss , Pp 68-75 (2022)
Background: After radical prostatectomy (RP), depending on stage, up to 40% of patients with prostate cancer (PCa) will experience biochemical failure (BF). Despite salvage therapy, approximately one-third of these patients will need permanent hormon
Externí odkaz:
https://doaj.org/article/4bb9e8665eca453fb6a2b5e1d3055677